How much does a box of generic sotorasib cost?

Sotorasib is a new type of anti-cancer drug and a targeted therapy drug in the field of tumor treatment. It is primarily used to treat patients with advanced non-small cell lung cancer (NSCLC) who have the KRAS G12C mutation, a common and difficult-to-treat subtype of lung cancer.

The original drug of sotorasibu has not yet been launched in China, so patients cannot purchase it domestically and need to purchase sotorasibu through overseas channels. The price of the original research version of sotorasibu in Hong Kong, China, is 120mg*240 tablets, which is around 8 million. The price of the European version of the original research drug with the same specifications is around 4 million, which is relatively expensive. The cheaper ones are the generic drugs marketed abroad. For example, the price of generic drugs in Laos and Bangladesh is around two to three thousand yuan. The price is relatively cheap, and the ingredients of foreign generic drugs are basically the same as the original drugs.

The KRAS G12C mutation is a common cancer driver gene mutation, and sotorasiib is designed to specifically interfere with this mutation, thereby inhibiting the growth and spread of tumor cells. Compared with traditional chemotherapy drugs, sotoracib has a more precise mechanism of action, allowing it to attack cancer cells more selectively and reduce damage to normal cells, thereby improving patients' survival rate and quality of life.

The development of this drug represents a milestone in the field of cancer treatment because the KRAS G12C mutation has long been considered a difficult cancer mutation to intervene. The launch of sotorasiib fills a gap in this area and provides a new treatment option for those patients with this specific mutation.

However, it is important to note that sotorasiib is not suitable for all patients with non-small cell lung cancer, but only for those carrying the KRAS G12C mutation. When using this drug, doctors need to use genetic testing to confirm whether the patient is suitable for treatment with sotoraxib to ensure optimal efficacy and safety.

xa0